Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Back to the list Next article Previous article

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Download Publication

Twitter

Facebook

You might also be interested by

Scientific Publications

New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy

April 11, 2024

More info

Posters

Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform

April 8, 2024

More info

Posters

Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response

April 8, 2024

More info

Posters

Deployment of a visualization tool directly linked to CellEngine cytometry analysis software to accelerate analysis of complex cytometry data sets in the context of ongoing clinical trials

April 8, 2024

More info

You might also be interested by

New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy

Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform

Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response

Deployment of a visualization tool directly linked to CellEngine cytometry analysis software to accelerate analysis of complex cytometry data sets in the context of ongoing clinical trials

New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy